There are currently 48 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
NCT06548672
Recruiting
This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression or intolerance). This study will consist of two parts: Dose escalation (Part 1) and dose expansion (Part 2). Each part will include a screening period, a treatment period, and follow-up period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2024
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Advanced Cancer, Metastatic Solid Tumor
Register for Updates
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575
Recruiting
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Providence Medical Foundation - Research, Santa Rosa, California +119 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Register for Updates
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Mayo Clinic, Phoenix, Arizona +10 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +10 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
Register for Updates
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080
Recruiting
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Florida Cancer Specialists, Lake Mary, Florida +15 locations
Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Register for Updates
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +19 locations
Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Register for Updates
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
NCT05663710
Recruiting
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer, Clear Cell Renal Cell Carcinoma
Register for Updates
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado +9 locations
Conditions: Advanced Cancer
Register for Updates
Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer
NCT07105033
Recruiting
To learn about the effects of an intervention program called Focused Acceptance and Commitment Therapy (FACT) on the level of anxiety patients diagnosed with cancer feel about death. To learn if an intervention program called Focused Acceptance and Commitment Therapy (FACT), designed to help reduce death-related anxiety, is effective and acceptable to patients diagnosed with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama +227 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)
NCT06870617
Recruiting
The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PG... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
07/10/2025
Locations: Penn Medicine Princeton Medical Center, Princeton, New Jersey +2 locations
Conditions: Geriatric Assessment, Advanced Cancer, Toxicity
Register for Updates
Psilocybin in Cancer Pain Study
NCT06001749
Recruiting
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Register for Updates